Coexistence of Epidermal Growth Factor Receptor 19 Deletion and 21 Point Mutation in Nonsmall Cell Lung Cancer: A Report of 3 Cases

  • Lu Yunyun Department of Geriatrics, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, China.
Keywords: Epidermal growth factor receptor mutation, epidermal growth factor receptor tyrosine kinase inhibitor, nonsmall cell lung

Abstract

The coexistence of an epidermal growth factor receptor (EGFR) 19 deletion and 21 point mutation represents a rare event in patients with nonsmall cell lung cancer. We present three cases of female patients with lung adenocarcinoma who had the double genetic mutations. The patients were all treated with EGFR tyrosine kinase inhibitors (TKIs) because the tumors were judged inoperable. In all cases, tumor progression occurred after a few months. Further studies are needed to determine whether the EGFR‑TKI resistance time in patients with double genetic mutations is longer than that in patients with a single mutation.

Published
2018-09-28
How to Cite
Yunyun, L. (2018). Coexistence of Epidermal Growth Factor Receptor 19 Deletion and 21 Point Mutation in Nonsmall Cell Lung Cancer: A Report of 3 Cases. International Journal of Clinical and Experimental Physiology, 4(3), 157-159. Retrieved from https://ijcep.org/index.php/ijcep/article/view/218